Cardiovascular remodelling, defined as ventricular and vascular hypertrophy together with fibrosis, characterises hypertension following inhibition of the production of the endogenous vasodilator, nitric oxide (NO). This study has determined whether the cardiovascular remodelling following chronic NO synthase inhibition can be reversed by administration of the selective angiotensin II AT 1 -receptor antagonist, candesartan. Male Wistar rats were treated with L-nitroarginine methyl ester (L-NAME, 400 mg/l in drinking water) for eight weeks and with candesartan cilexetil (2 mg/kg/day by oral gavage) for the last four weeks. L-NAME-treated rats became hypertensive with systolic blood pressure increasing from 110±4 mmHg (control) to 170±10 mmHg. Rats developed left ventricular hypertrophy (control 1.70±0.06; L-NAME 2.10±0.04 mg/kg body wt) with markedly increased deposition of perivascular and interstitial collagen. Candesartan returned blood pressure, left ventricular weights and collagen deposition to control values. Echocardiographic assessment showed concentric hypertrophy with an increased fractional shortening; this was reversed by candesartan treatment. Heart failure was not evident. In the isolated Langendorff heart, diastolic stiffness increased in L-NAME-treated rats while the rate of increase in pressure (+dP/dt) increased after eight weeks only; candesartan reduced collagen deposition and normalised +dP/dt. In isolated left ventricular papillary muscles, the potency (negative log EC 50 ) of noradrenaline as a positive inotropic compound was unchanged, (control 6.56±0.14); maximal increase in force before ectopic beats was reduced from 5.0±0.4 mN to 2.0±0.2 mN. Noradrenaline potency as a vasoconstrictor in thoracic aortic rings was unchanged, but maximal contraction was markedly reduced from 25.2±2.0 mN to 3.0±0.3 mN; this was partially reversed by candesartan treatment. Thus, chronic inhibition of NO production with L-NAME induces hypertension, hypertrophy and fibrosis with increased toxicity and significant decreases in vascular responses to noradrenaline. These changes were at least partially reversible by treatment with candesartan, implying a significant role of AT 1 -receptors in L-NAME-induced cardiovascular changes.
Introduction
Regulation of vascular tone in vivo requires a balance between the release of vasoconstrictors, for example angiotensin II (Ang II) and endothelin, and vasodilators such as nitric oxide (NO). However, NO has a much broader role in physiological processes in the cardiovascular system, modulating cardiac contractility, 1 myocardial relaxation and diastolic function. 2 NO is produced in vascular endothelial cells from L-arginine by NO synthase. In rats, NO synthase inhibition by arginine analogues such as Nω-nitro L-arginine methyl ester (L-NAME) induces hypertension, ventricular hypertrophy and cardiac fibrosis, defined as cardiovascular remodelling. 3 The degree of hypertrophy is modest but may be absent;
Bartunek et al. 4 have described maintenance of left ventricular function in chronic L-NAME-treated hypertensive rats by chamber remodelling despite unchanged ventricular weights.
Ang II is also a key modulator of cardiovascular function 5 and may modulate the actions of NO. 6 In chronic L-NAME-treated rats, concurrent administration of either an ACE-I, temocapril, or a selective angiotensin AT 1 -receptor antagonist, CS-866, were equally effective in preventing remodelling. 3 Further studies from this group have shown that ventricular AT 1 -receptors were upregulated during the first week of treatment with L-NAME but returned to control levels after four weeks. 7 The AT 1 -antagonist, CS-866, prevented inflammatory cell infiltration, monocyte chemoattractant protein-1 expression, nuclear factor κB activity and increased superoxide production, indicating that AT 1 -receptors are important in the early inflammatory changes in the L-NAME-treated rat. 8 Thus, AT 1 -receptor activation plays an important role in the initial responses in the heart following inhibition of NO synthase by L-NAME.
Cardiovascular remodelling is a chronic response leading to functional impairment of the heart. 9 Reversal of excessive hypertrophy and fibrosis, rather than prevention, is more clinically relevant, but only if this reversal is accompanied by an improvement in cardiac function. We have previously shown that reversal of fibrosis in the DOCA-salt hypertensive rat heart improved cardiac function. 10 In the current study, we have characterised the cardiovascular remodelling associated with hypertension produced by chronic L-NAME treatment in rats. Further, we have investigated whether oral administration of the selective AT 1 -receptor antagonist, candesartan cilexetil, can reverse hypertension and cardiac remodelling as well as normalise cardiac function. To do this, we have defined changes in blood pressure, ventricular weight and cardiac structure, especially collagen deposition, and cardiac function using echocardiography in vivo and the isolated perfused Langendorff heart ex vivo.
Materials
L-NAME and noradrenaline were purchased from Sigma Chemical Company, St Louis, MO, USA and dissolved in distilled water. Candesartan cilexetil was generously provided by AstraZeneca R&D, Mölndal, Sweden.
Methods
Male Wistar rats (8-10 week old) (n=108) were obtained from the Central Animal Breeding House of The University of Queensland. All experimental protocols were approved by the Animal Experimentation Ethics Committee of The University of Queensland. Experiments were performed after four or eight weeks treatment with L-nitroarginine methyl ester (L-NAME, 400 mg/l in drinking water, n=37). After four weeks of L-NAME treatment, rats were given candesartan (2 mg/kg/day by oral gavage) for a further four weeks (n=28). Age-matched control rats were also given candesartan (2 mg/kg/day by oral gavage) for four weeks (n=18) or untreated (n=25). Food and water intake and body weight were measured daily for all rats. Systolic blood pressure was measured by tail-cuff plethysmography with a MacLab unit (AD Instruments, Sydney, Australia) and computer.
Collagen distribution
Collagen distribution was determined by image analysis of picrosirius red (0.1% Sirius Red F3BA in saturated picric acid)-stained sections of heart and kidney. Slides were left in 0.2% phosphomolybdic acid for 5 minutes, washed, left in picrosirius red for 90 minutes, then in 1 mM HCl for 2 minutes and 70% ethanol for 45 seconds. The stained sections were analysed with an Image Pro plus analysis program, using an Olympus BH2 microscope, with results expressed as a percentage of red area in each screen. At least four areas were examined in each heart.
Isolated Langendorff heart preparation
Rats were anaesthetised with sodium pentobarbitone (100 mg/kg i.p.) and heparin (2000 IU) was administered via the femoral vein. After allowing 5 minutes for the heparin to fully circulate, the heart was excised and placed in cooled (0 o C) crystalloid perfusate (Krebs Henseleit bicarbonate buffer with the following composition [mM]: NaCl 118, KCl 4.7, MgSO 4 1.2, KH 2 PO 4 1.2, CaCl 2 2.3, NaHCO 3 25.0, glucose 11.0).The heart was then attached to the cannula (with the tip of the cannula positioned immediately above the coronary ostia of the aortic stump) and perfused in a non-recirculating Langendorff mode at 100 cm of hydrostatic pressure. The buffer temperature was maintained at 37 o C.The hearts were punctured at the apex to facilitate thebesian drainage.
A balloon catheter was inserted in the left ventricle via the mitral orifice for measurement of left ventricular developed pressure. The catheter was connected via a three-way tap to a micrometer syringe and to a Statham P23 pressure transducer. The outer diameter of the catheter was similar to the mitral annulus to prevent ejection of the balloon during the systolic phase. After a 10 minute stabilisation period, steady-state left ventricular pressure was recorded from isovolumetrically beating hearts. Increments in balloon volume were applied to the heart until left ventricular end-diastolic pressure reached approximately 30 mmHg. At the end of the experiment, the atria and right ventricle were dissected away and the weight of the left ventricle plus septum was recorded.
Isolated cardiac muscles and thoracic aortic rings
The heart was removed under anaesthesia. The right atria and papillary muscles from the left ventricle were removed and suspended in organ baths at a resting tension of 5-10 mN, adjusted to give the maximal twitch response. Tissues were bathed in a modified Tyrodes solution (containing, mM): NaCl 136.9, KCl 5.4, MgCl 2 1.05, CaCl 2 1.8, NaHCO 3 22.6, NaH 2 PO 4 0.42, glucose 5.5, ascorbic acid 0.28, sodium edetate 0.05, bubbled with 95% O 2 /5% CO 2 and stimulated at 1Hz at 35ºC as previously described. 11 Cumulative concentrationresponse curves were measured for noradrenaline and, following washout and re-equilibration, for calcium chloride. At the end of the experiment, papillary muscle dimensions were measured under the loading conditions of the experiment; all tissues were blotted and weighed.
Thoracic aortic rings (approximately 4 mm in length) were suspended with a resting tension of 10 mN 12 and contracted twice with isotonic KCl (100 mM). The presence of endothelium was demonstrated by addition of acetylcholine (1x10 -5 M). Cumulative contraction responses to noradrenaline or 5-hydroxytryptamine were measured. Separate thoracic aortic rings were perfused with 10% neutral buffered formalin, embedded in wax and stained with haemotoxylin and eosin. Image analysis (Wild-Leitz MD30+ system) was used to calculate the wall area of the thoracic aorta.
Echocardiography
Left parasternal and left apical echocardiographic images were obtained using a Hewlett Packard Sonos 5500 (12 MHz transducer) at an image depth of 3 cm, using two focal zones. The short axis of the left ventricle at the level of the papillary muscles was used for 2D-guided digitised M-mode measurements of systolic and diastolic wall thicknesses and left ventricular internal diameters. Pulsed-wave Doppler velocities of the ascending and descending aorta and mitral valve inflows were measured.
Data analysis
All results are given as mean ±SEM of at least six experiments. The negative log EC 50 of the increase in either force of contraction (in mN) or rate of contraction (in beats/min) was determined from the concentration giving half-maximal responses in S142
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To assess myocardial stiffness in isolated Langendorff hearts, stress (σ, dyne/cm 2 ) and tangent elastic modulus (E, dyne/cm 2 ) for the midwall at the equator of the left ventricle were calculated, using equations as previously described. 10 Myocardial diastolic stiffness is calculated as the diastolic stiffness constant (k, dimensionless), the slope of the linear relation between E and σ. 13 To assess contractile function, maximal dP/dt was calculated at a diastolic pressure of 10 mmHg. Data are presented as mean ± standard error of the mean. Comparisons of the group means were made by oneway ANOVA with a Newman-Keuls post test; p<0.05 was considered significant.
Results
Chronic, continuous oral administration of L-NAME to eight-week old rats for eight weeks did not alter their rate of growth ( Figure 1 ) nor their food or water intake ( Table 1 ). Addition of candesartan for the last four weeks did not alter these parameters (Figure 1 ). The daily dosage of L-NAME was constant at 40.6±0.4 mg/kg in rats treated with L-NAME only and 41.6±0.1 mg/kg in rats additionally treated with candesartan over the eight-week period. Since candesartan did not change water consumption, L-NAME dosage remained constant ( Figure 1 ).
Administration of L-NAME induced moderate hypertension ( Figure 2 ) and increased left ventricular wet weight without altering kidney or liver wet weights (Table 1) . Echocardiography demonstrated concentric ventricular hypertrophy with an increased left ventricular wall thickness and decreased left ventricular internal diameter together with an increased fractional shortening in the last four weeks of L-NAME treatment ( Figure  3 ). Candesartan treatment normalised these changes in wall thickness and fractional shortening, without altering internal diameter ( Figure 3 ). Cardiac output was used as an estimate of systolic function, while diastolic function was estimated from mitral flow rates calculated as the ratio of the maximal E-and A-wave. Neither parameter was significantly changed by L-NAME or candesartan treatment (Figure 3 ), indicating that there is no evidence for the development of systolic or diastolic failure in these rats. Ventricular stiffness measured in the isolated Langendorff heart was significantly increased by treatment with L-NAME after both four and eight weeks treatment; this parameter was also normalised by administration of candesartan in the last four weeks (Figure 4 ). Contractility, measured as rate of rise of pressure (+dP/dt) in these hearts, was increased after eight weeks only (Figure 4) , as was fractional shortening in the echocardiographic assessment. Candesartan in control rats caused a small increase in +dP/dt but normalised this parameter in L-NAME-treated rats (Figure 4 ). L-NAME treatment significantly increased both perivascular and interstitial collagen deposition in the left ventricle. Administration of candesartan after four weeks for a four-week period decreased ventricular collagen deposition, although values were still significantly higher than in candesartantreated control rats ( Figure 5 ).
Noradrenaline produced arrhythmias at lower concentrations in papillary muscles from L-NAME treated rats although positive inotropic responses were unchanged ( Figure 6 ). Contractile responses to noradrenaline in thoracic aortic rings were decreased; candesartan treatment improved noradrenaline responses ( Figure 6 ).
Discussion
Modulation of vascular tone by altering either Ang II or NO levels is clearly important in the therapy of cardiovascular disease. As examples, ACE-I and angiotensin receptor antagonists are widely used in hypertension and heart failure, while NO donors such as glyceryl trinitrate have been used for more than a century in the treatment of angina pectoris. In contrast, activation of the reninangiotensin aldosterone system (RAAS), 5 or inhibiting the production of NO, 14 has been implicated as a cause of cardiovascular diseases, in particular hypertension, heart failure and atherosclerosis. This project has clearly shown that the cardiovascular changes following inhibition of NO production can be reversed by the selective AT 1 -receptor antagonist, candesartan. This strongly suggests both that an up-regulation Endogenous NO and Ang II have many opposing effects on the cardiovascular system: NO produces localised vasodilator and antiproliferative responses, while Ang II produces vasoconstrictor and mitogenic responses.There is now good evidence that the two mediators are much more integrated; for example, NO inhibits ACE activity and down-regulates AT 1 -receptors while Ang II stimulates NO synthesis and release. 6 These results have relied on experiments with chronic dosing, usually for four to eight weeks, of rats with an inhibitor of NO synthase such as L-NAME. 15 Many groups have shown that this treatment regimen produces moderate hypertension, thickening of the media of blood vessels, perivascular and myocardial fibrosis and ventricular hypertrophy. 3, 16 However, the degree of ventricular hypertrophy, measured by postmortem wet weights, in our study is modest (9% after four weeks, 20% after eight weeks) when compared with other models of hypertrophy in the young adult rat, such as hyperthyroidism (42% increase in wet weights after seven days, 61% after 14 days). 17 This is consistent with the study of Bartunek et al. 4 and previous studies cited by these workers which show absent or modest changes in left ventricular mass in L-NAME-treated rats, despite sustained hypertension. Bartunek et al. 4 show that left ventricular function is maintained by left ventricular remodelling, especially decreased chamber dimensions relative to wall thickness, and enhanced contractility in response to calcium.
Echocardiography with Doppler assessment of blood flow is the method of choice to estimate the left ventricular geometry and function of the human heart in the diagnosis of cardiovascular disease. These determinations are noninvasive and can be measured serially in the same patient. These advantages also apply to echocardiographic and Doppler measurements in rats. Litwin et al. 18 showed that aortic banding increased left ventricular wall thickness after six weeks, with a mild depression of fractional shortening and a restrictive diastolic filling pattern.After 18 weeks, heart failure was evident as cavity dilatation, a fall in endocardial shortening and further deterioration in diastolic filling. Treatment of these rats with an ACE-I, fosinopril, prevented the changes in cavity dimension while systolic and diastolic function either did not deteriorate or improved. Cardiac changes following coronary artery ligation as a model of myocardial infarction (MI) have been followed using echocardiography. Both candesartan and the ACE-I, cilazapril, were equally effective in preventing increases in hypertrophy in the noninfarcted myocardium and left ventricular dilatation, as well as preventing increases in the E-wave/A-wave ratio following MI in rats. 19 Echocardiographic assessment in our study has shown reversal of changes in ventricular geometry with no evidence for the development of heart failure during eight weeks of L-NAME treatment.
The changes in structure following L-NAME treatment were associated with increased cardiac stiffness and decreased ventricular contractility in the isolated heart.These changes may correspond to the increased collagen deposition, although Norton et al. 20 have shown that collagen crosslinking, rather than total collagen, is important for the increased stiffness of SHR hearts. Further, isolated ventricular tissues from L-NAME-treated rats were more likely to develop arrhythmias with noradrenaline, as we have previously shown in rats with hypertrophy associated with chronic noradrenaline infusion 21 and isolated thoracic aortic rings showed decreased contractile responses. Treatment of L-NAME hypertensive rats with candesartan returned all functional and structural parameters towards control values, although normalisation was not achieved. Thus, unopposed responses to circulating vasoconstrictors, especially Ang II, in the absence of NO may explain the pathophysiological changes in L-NAME-treated rats. 22 Ang II may be the predominant, rather than the only vasoconstrictor involved in chronic responses, since A-127722, an endothelin receptor (ET A ) antagonist, prevented the subchronic (four-day) responses to L-NAME but not the chronic responses. 23 Endothelin produces hypertension and cardiovascular remodelling similar to Ang II. The inability of candesartan treatment to completely reverse collagen deposition in our study may simply reflect that four weeks' therapy is insufficient to remove the stable cross-linked collagen. It is also possible that the residual collagen deposition and functional deficits are due to increased endothelin concentrations which are unaffected by candesartan treatment.
Since AT 1 -receptor blockade normalised both blood pressure and structural changes in L-NAMEtreated rats, it is plausible that the structural and functional improvements resulted from the decrease in blood pressure per se. We have previously reported that candesartan treatment of DOCA-salt hypertensive rats produced reversal of fibrosis and improved cardiac function without regression of hypertension or ventricular hypertrophy, showing that hypertension and cardiac remodelling are independent events, at least in this model. 10 This issue could be further investigated by chronic treatment of L-NAME hypertensive rats with antihypertensive drugs which act independently of the RAAS, such as prazosin or α-methyldopa.
Few groups have studied regression of hypertrophy in hypertensive rats. Spontaneous recovery for three weeks, following a four week treatment with L-NAME, led to regression of hypertension but not hypertrophy. 15 However, captopril treatment in the regression phase led to complete regression of both hypertension and hypertrophy, though collagen content remained increased. This further suggests that hypertension and remodelling are independent events.
In summary, the current study shows that it is feasible to reverse both existing structural and functional changes in hypertension, as well as prevent further progression. This has obvious clinical relevance, since the aim of therapy in hypertension is to return cardiovascular function to normal, prevent further end-organ damage and not merely to lower an elevated blood pressure.
Figure 6
Cumulative concentration-response curves for noradrenaline in left ventricular papillary muscles (above) and thoracic aortic rings (below) from control (C, open circles), candesartan-treated control (CCand), L-NAMEtreated (N, filled circles) and candesartan-and L-NAMEtreated (NCand, filled triangles) rats. 
